Non-Antibiotic Treatment for Equine Endometritis Study Data Published in International Peer-Reviewed Journal
- data shows up to 70% efficacy using a controlled challenge model -
BELLEVILLE, ON, April 3 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has had an article published in the Journal of Equine Veterinary Science outlining the effectiveness of its Mycobacterial Cell Wall Extract (MCWE) in the treatment of endometritis in a challenge study with susceptible mares. The Journal of Equine Veterinary Science is an international publication designed for the practicing equine veterinarian, equine researcher, and other equine health care specialist.
Endometritis is a non-life threatening bacterial infection that affects 25% to 30% of broodmares worldwide. The disease results in low conception rates or loss of pregnancies if conception occurs. If not successfully treated during the acute phase (conventional treatment involves intrauterine or intravenous antibiotics for three to four consecutive days), the original infection can result in a chronic, degenerative inflammatory condition compromising future fertility and requiring a laborious and costly battery of treatments.
The study outlined in the Journal of Equine Veterinary Science was conducted by Dr. Dragan Rogan, Vice-President of Research & Development, Bioniche Animal Health, with E. Fumoso, E. Rodriguez, J. Wade, and S.F. Sanchez Bruni. After being inoculated with Streptococcus zooepidemicus, thirty mares randomly received either the Bioniche MCWE (SettleTM) or placebo by both intravenous and intrauterine modes of administration. Mares were examined at ovulation and 7 days post-ovulation. Experimental bacterial infections resulting in endometritis were observed in all placebo-treated mares, whereas treatment with Settle resulted in the elimination of endometritis in 35% of the mares by the time of ovulation and 70% of the mares by 7 days post-ovulation.
"Typically, mares with endometritis are treated with antibiotics," noted Dr. Rogan. "There is a growing desire to minimize antibiotic use because of concerns about microbial resistance. Settle offers a safe, effective, and convenient stand-alone therapy for endometritis in mares. Both intrauterine and intravenous routes of administration proved effective."
About the Mycobacterial Cell Wall Technology Platform
Bioniche's core mycobacterial cell wall technology platform comprises a number of different compositions with a spectrum of activity that comprises antiviral, antibacterial, immune stimulatory and immune adjuvant, as well as anticancer and chemotherapeutic activity against cancer cells. A number of formulations are commercialized for use in veterinary applications, including Settle, which was approved by the U.S. Department of Agriculture (USDA) in 2004 for the treatment of equine endometritis caused by Streptococcus zooepidemicus.